Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

[1]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  L. Gullo,et al.  Tumor M2-Pyruvate Kinase, a New Metabolic Marker for Pancreatic Cancer , 2004, Digestive Diseases and Sciences.

[3]  H. Tao,et al.  Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[4]  Jun Wu,et al.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. , 2004, World journal of gastroenterology.

[5]  Caj Haglund,et al.  Serum HCGβ and CA 72-4 Are Stronger Prognostic Factors than CEA, CA 19-9 and CA 242 in Pancreatic Cancer , 2004, Oncology.

[6]  J. K. Lee,et al.  Clinical usefulness of carbohydrate antigen 19‐9 as a screening test for pancreatic cancer in an asymptomatic population , 2004, Journal of gastroenterology and hepatology.

[7]  J. Schneider,et al.  Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. , 2003, Anticancer research.

[8]  J. Neoptolemos,et al.  Prediction of resectability of pancreatic malignancy by computed tomography , 2003, The British journal of surgery.

[9]  C. Haglund,et al.  CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. , 2002, Anticancer research.

[10]  P. Hardt,et al.  Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. , 2000, Anticancer research.

[11]  G. Schulze.  The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. , 2000, Anticancer research.

[12]  A. Bozdağ,et al.  The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. , 2000, Hepato-gastroenterology.

[13]  D Delbeke,et al.  EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. , 2000, Gastrointestinal endoscopy.

[14]  R. Edwards,et al.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  A. van Dalen,et al.  Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis , 2000, Cancer.

[16]  S. Myung,et al.  A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve , 1999, American Journal of Gastroenterology.

[17]  Á. Ruibal,et al.  Comparative Study of Carbohydrate Antigen 195 and Carcinoembryonic Antigen for the Diagnosis of Pancreatic Carcinoma , 1999, World Journal of Surgery.

[18]  H. Ishiguro,et al.  A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases , 1999, International journal of pancreatology : official journal of the International Association of Pancreatology.

[19]  U. Schmiedl,et al.  Pancreatic arterial anatomy: depiction with dual-phase helical CT. , 1998, Radiology.

[20]  D. Lu,et al.  Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. , 1998, AJR. American journal of roentgenology.

[21]  K. Kopecky,et al.  Value of helical computed tomography, angiography, and endoscopic ultrasound in determining resectability of periampullary carcinoma. , 1997, American journal of surgery.

[22]  S. Zeuzem,et al.  Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. , 1997, Anticancer research.

[23]  S. Gansauge,et al.  CAM 17.1--a new diagnostic marker in pancreatic cancer. , 1996, British Journal of Cancer.

[24]  V. Zurawski,et al.  Comparison of Preoperative Serum CA19‐9 Levels with Results of Diagnostic Imaging Modalities in Patients Undergoing Laparotomy for Suspected Pancreatic or Gallbladder Disease , 1994, Pancreas.

[25]  T. Takeuchi,et al.  Comparison of CA19‐9 with Other Tumor Markers in the Diagnosis of Cancer of the Pancreas , 1994, Pancreas.

[26]  Y. Horiguchi,et al.  Effectiveness of Multivariate Analysis of Tumor Markers in Diagnosis of Pancreatic Carcinoma: A Prospective Study in Multiinstitutions , 1994, Pancreas.

[27]  T. Homma,et al.  CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience , 1994, Pancreas.

[28]  S. Kawa,et al.  Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. , 1994, British Journal of Cancer.

[29]  C. Haglund,et al.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. , 1994, British Journal of Cancer.

[30]  H. Thornes,et al.  Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction. , 1994, Gut.

[31]  A. Andrén-sandberg,et al.  The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases. , 1993, Scandinavian journal of gastroenterology.

[32]  A. Watanabe,et al.  Clinical usefulness of computer‐assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma , 1993, Cancer.

[33]  H. Friess,et al.  CA 494—a new tumor marker for the diagnosis of pancreatic cancer , 1993, International journal of cancer.

[34]  U. Harmenberg,et al.  Serum Levels of CA 19‐9 and CA 50 in Relation to Lewis Blood Cell Status in Patients with Malignant and Benign Pancreatic Disease , 1993, Pancreas.

[35]  G. Banfi,et al.  Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. , 1993, Clinical chemistry.

[36]  H. Joller,et al.  CA 242 is a new tumor marker for pancreatic cancer , 1993, Cancer.

[37]  M. Plebani,et al.  Extra‐hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases , 1992, European journal of clinical investigation.

[38]  O. M. Taylor,et al.  A new enzyme‐linked lectin/mucin antibody sandwich assay (CAM 17.1/ WGA) assessed in combination with CA 19‐9 and peanut lectin binding assay for the diagnosis of pancreatic cancer , 1992, Cancer.

[39]  C. Lightdale,et al.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.

[40]  K. Partanen,et al.  Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. , 1992, British Journal of Cancer.

[41]  A. Andrén-sandberg,et al.  Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. , 1992, British Journal of Cancer.

[42]  C. Niederau,et al.  Diagnosis of Pancreatic Carcinoma: Imaging Techniques and Tumor Markers , 1992, Pancreas.

[43]  S. Kawa,et al.  Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer. , 1991, Scandinavian journal of gastroenterology.

[44]  C. Haglund,et al.  A retrospective analysis of submissions, acceptance rate, open peer review operations, and prepublication bias of the multidisciplinary open access journal Head & Face Medicine , 2006, PLoS biology.

[45]  K. Endo,et al.  Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. , 1990, The American journal of gastroenterology.

[46]  J. Balibrea,et al.  Tumor Markers in Pancreatic Cancer: A Comparative Clinical Study between CEA, CA 19-9 and CA 50 , 1990, The International journal of biological markers.

[47]  M. Kitagawa,et al.  Usefulness of a new tumor marker, span‐1, for the diagnosis of pancreatic cancer , 1990, Cancer.

[48]  T. Yoshikawa,et al.  Enzyme immunoassay of pancreatic oncofetal antigen (POA) as a marker of pancreatic cancer. , 1985, Gut.

[49]  H. Koprowski,et al.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.

[50]  R. Santambrogio,et al.  A Prospective Study , 2006 .

[51]  H. Mischinger,et al.  TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. , 1999, Anticancer research.

[52]  R. Tsuchiya,et al.  The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in japan, using ca19-9 and elastase-1 or ultrasonography , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.